Latest Report Overview for Intellia Therapeutics Inc ($NTLA)
AI-powered analysis of Intellia Therapeutics Inc (NTLA) stock based on Q2 2026 financial data.
Latest Report Overview
Intellia Therapeutics Inc (NTLA) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $8 million with diluted EPS of $-0.80 and net income of $-107 million. Operating margin was -1472.3%, and free cash flow was $-85 million for the period.
Key Takeaways for Intellia Therapeutics Inc
- Reported Q2 2026 revenue of $7.66 million, reflecting a significant 46.2% decline YoY as collaboration milestones fluctuated.
- Maintained an intensive R&D program with $82.60 million in spending during Q2 2026, underlining the company's commitment to advancing its clinical pipeline.
- Net loss of $106.63 million in Q2 2026 demonstrates the ongoing cash burn required for sustained clinical development in the genome editing space.
- Cash position stands at $106.13 million as of June 30, 2026, which remains a critical watch-item for liquidity and future financing needs.
- Strategic focus remains on key clinical assets including NTLA-2001 and NTLA-2002, which are the primary drivers of long-term value creation.
- Operating cash flow remains negative at -$83.11 million for Q2 2026, consistent with a clinical-stage biotechnology company's capital allocation model.
What Does Intellia Therapeutics Inc Do?
Intellia Therapeutics is a clinical-stage genome editing company that leverages CRISPR/Cas9 technology to develop potentially curative therapies. The company focuses on two primary areas: in vivo applications, which edit genes directly within the body to treat systemic diseases, and ex vivo applications, which engineer cells outside the body for potential treatment of cancers and autoimmune disorders. Intellia's business model is centered on building a robust pipeline of therapeutic candidates while securing strategic partnerships to share the costs and risks of development. The company operates as a research-intensive enterprise, primarily serving the biopharmaceutical industry through collaboration agreements and targeting patients with unmet medical needs in various genetic and disease-specific markets. Its scale is characterized by high human capital investment in scientific and clinical expertise rather than large-scale commercial manufacturing.
Growth Drivers for Intellia Therapeutics Inc
- Clinical progression and readout success for key pipeline candidates like NTLA-2001 and NTLA-2002.
- Strategic collaborations and licensing deals with major pharmaceutical companies providing milestone revenue.
- Expanding the application of its proprietary CRISPR/Cas9 platform into new, high-value disease indications.